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Abstract
AIM
To evaluate the impact of sepsis and non-communicable diseases (NCDs) on the
outcome of decompensated chronic liver disease (CLD) patients.
METHODS
In this cross-sectional study, medical records of patients with CLD admitted to
the Gastroenterology unit at the Aga Khan University Hospital were reviewed.
Patients older than 18 years with decompensation of CLD (i.e., jaundice, ascites,
encephalopathy, and/or upper gastrointestinal bleed) as the primary reason for
admission were included, while those who were admitted for reasons other than
decompensation of CLD were excluded. Each patient was followed for 6 wk after
index admission to assess mortality, prolonged hospital stay (> 5 d), and early
readmission (within 7 d).
RESULTS
A total of 399 patients were enrolled. The mean age was 54.3 ± 11.7 years and
64.6% (n  = 258)  were male.  Six-week mortality was 13% (n  = 52).  Prolonged
hospital stay and readmission were present in 18% (n = 72) and 7% (n = 28) of
patients, respectively. NCDs were found in 47.4% (n = 189) of patients. Acute
kidney injury, sepsis, and non-ST elevation myocardial infarction were found in
41% (n = 165), 17.5% (n = 70), and 1.75% (n = 7) of patients, respectively. Upon
multivariate  analysis,  acute  kidney  injury,  non-ST  elevation  myocardial
infarction, sepsis, and coagulopathy were found to be statistically significant
predictors of mortality. While chronic kidney disease (CKD), low albumin, and
high Model for End-Stage Liver Disease (MELD)-Na score were found to be
statistically significant predictors of morbidity. Addition of sepsis in conventional
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MELD score predicted mortality even better than MELD-Na (area under receiver
operating characteristic: 0.735 vs 0.686; P < 0.001). Among NCDs, CKD was found
to increase morbidity independently.
CONCLUSION
Addition of sepsis improved the predictability of MELD score as a prognostic
marker  for  mortality  in  patients  with  CLD.  Presence  of  CKD  increases  the
morbidity of patients with CLD.
Key words:  Chronic  liver  disease;  Mortality;  Morbidity;  Prognostic  factors;  Non-
communicable diseases; Sepsis
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Chronic liver disease is one of the leading causes of mortality. Child-Pugh
and  Model  for  End-Stage  Liver  Disease  scores  have  been  designed  to  predict  the
outcome in cirrhotic patients. Infection and renal insufficiency can worsen the outcome
in cirrhotic patients. Myocardial infarction, sepsis,, and coagulopathy are associated with
poor  outcomes  in  patients  with  cirrhosis.  The  addition  of  sepsis  can  improve  the
predictability of the Model for End-Stage Liver Disease score as a prognostic marker for
mortality in hospitalized patients with liver cirrhosis. Presence of chronic kidney disease
increased  the  morbidity  of  cirrhotic  patients.  There  is  no  direct  impact  of  non-
communicable disease over mortality in hospitalized patients with liver cirrhosis.
Qazi Arisar FA, Abid S, Shaikh PA, Awan S. Impact of sepsis and non-communicable
diseases on prognostic models to predict the outcome of hospitalized chronic liver
disease patients. World J Hepatol 2018; 10(12): 944-955
URL: https://www.wjgnet.com/1948-5182/full/v10/i12/944.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i12.944
INTRODUCTION
The  massive  global  burden  of  chronic  liver  disease  (CLD)  has  been  well
documented[1], with more than one million deaths per year worldwide[2] making it the
14th leading cause of death globally[3]. Many prognostic models have been developed
over  the  years  to  help  classify  the  severity  of  liver  disease  and  direct  the
aggressiveness of medical care. The Child-Pugh Turcotte (CTP) Score and the Model
for  End-Stage  Liver  Disease  (MELD)  score  are  two of  the  most  commonly  used
scoring systems worldwide[4-6].
Child and Turcotte proposed the CTP score initially using nutritional status, the
presence  of  ascites,  hepatic  encephalopathy,  total  bilirubin,  and  albumin  as
parameters to determine mortality risk in patients undergoing portosystemic shunt
surgery. Later, Pugh et al[4] modified it to its current version by replacing nutritional
status with prothrombin time or international normalized ratio (INR), making it the
most  widely  used  scoring  system  for  estimation  of  prognosis  in  CLD  patients.
However,  the subjectivity of  variables (ascites,  encephalopathy) as well  as inter-
laboratory variability limited the accuracy of the CTP score, with the waitlist mortality
for liver transplantation continuing to rise[7].
MELD  score  was  introduced  primarily  to  determine  the  survival  of  patients
undergoing transjugular intrahepatic portosystemic shunt placement[5]. MELD score
incorporates total bilirubin, creatinine, and INR. It has not only become the mainstay
for prioritizing patients for liver transplant, but also for predicting mortality in non-
transplant surgical procedures, alcoholic hepatitis, and acute variceal hemorrhage[6,8].
However,  there are  still  several  comorbidities  such as  hepatocellular  carcinoma,
hepatopulmonary syndrome,  and portopulmonary hypertension (HTN) that  can
affect the prognosis of CLD patients and that are not taken into account by the MELD
score[9,10].
Several  studies  have  been  done  on  the  MELD score  with  proposals  made  for
revision of the scoring system to include other factors to improve the predictive
accuracy of the score. Some of these include modified CTP, MELD-Na, Reweighted
MELD and the Refit MELD, which have been shown to be superior to the current CTP
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and MELD scores[11-14]. Such studies have led several leading researchers to investigate
other variables and scoring systems to better predict mortality in patients hospitalized
for decompensated CLD.
Acute  kidney  injury  (AKI)  is  a  devastating  complication  that  is  frequently
progressive  and  independently  associated  with  mortality  in  a  stage-dependent
fashion in CLD patients[15]. Bacterial infections are common in liver disease, especially
in decompensated patients. Infections increase the mortality four-fold in patients with
end-stage liver disease[16]. Inflammation stemming from infections plays a key role in
the outcome of cirrhosis. The presence of systemic inflammatory response syndrome
with or without infection is a major predictor of prognosis in CLD patients[17].
There is an alarming rise in the prevalence of non-communicable diseases (NCDs)
worldwide. Diabetes, HTN, cardiovascular diseases, chronic obstructive pulmonary
diseases, and cancers have emerged as leading causes of mortality globally[18]. In a
recent cohort of the Asian population, diabetes was found to impact mortality in
cirrhotic patients[19].  However,  the effect  of other NCDs on the outcomes of liver
disease has not been elucidated.
Charlson et al[20] proposed a comorbidity index to predict all-cause mortality on the
basis of a number of comorbid conditions. Seventeen different diseases, each allocated
a score from one to six, are incorporated in the Charlson comorbidity index. The total
sum gives the total burden of comorbidities in that patient[20]. Since the 1980s, the
score has been extensively used to estimate mortality in a different subset of cohorts
including liver disease patients[21,22]. However, the severity of liver disease was not
incorporated in those studies.
The aim of this study is to evaluate the impact of NCDs on the outcome of patients
admitted for decompensated CLD. We also aimed to construct a model over and
above the existing scoring system.
MATERIALS AND METHODS
Study design and settings
This study employed a cross-sectional design. Medical records of CLD patients who
were admitted to the Gastroenterology unit at the Aga Khan University Hospital in
Karachi, Pakistan were reviewed. Patients older than 18 years with decompensation
of CLD (i.e.  jaundice, ascites, encephalopathy, and/or upper gastrointestinal (GI)
bleed) as the primary reason for admission were included. Those admitted for reasons
other than decompensation of CLD were excluded. Each patient was followed for 6
wk after index admission to assess mortality and morbidity. The study was conducted
after approval from the institutional ethical review committee.
Variables analyzed
(1) Demographics: age, gender, weight, duration of documented CLD, smoking, and
current alcohol use; (2) Clinical presentation: blood pressure, heart rate, temperature,
respiratory  rate,  Glasgow  coma  scale;  (3)  CLD  complications/decompensation:
presence  of  jaundice,  ascites,  encephalopathy,  esophageal  varices,  GI  bleeding,
hepatorenal  syndrome,  spontaneous bacterial  peritonitis,  and hepatopulmonary
syndrome;  (4)  NCDs:  Diabetes  mellitus,  HTN,  chronic  obstructive  lung disease,
ischemic heart disease, congestive heart failure, peripheral vascular disease, chronic
kidney  disease  (CKD),  cerebrovascular  disease  (prior  strokes),  acquired
immunodeficiency syndrome, cancer, dementia, connective tissue diseases, and peptic
ulcer  disease;  (5)  Laboratory  markers:  complete  blood  count,  electrolytes,  liver
function tests, serum albumin, creatinine, prothrombin time, C-reactive protein; (6)
Scoring Systems: Child-Pugh Score,  MELD score,  MELD-Na score,  and Charlson
comorbidity index. While calculating Charlson comorbidity index, patients with Child
A disease were given a score of 1 (mild), while those with Child B and C disease were
given  a  score  of  3  (moderate  to  severe)  as  per  standard  score;  and  (7)  Primary
outcome: To assess mortality within 6 wk of admission and morbidity defined as
either prolonged hospital stay > 5 d (120 h) or readmission within 7 d of the index
admission.
Operational definitions
Sepsis: Sepsis was defined as the presence of any source of infection along with at
least two of the following[23]: (1) Temperature > 38 °C (100.4 °F) or < 36 °C (96.8 °F); (2)
Heart rate > 90 bpm; (3) Respiratory rate > 20 or PaCO2 < 32 mmHg; and (4) Total
leukocyte count (TLC) > 12000/mm³, < 4000/mm³, or > 10% bands.
AKI:  AKI was defined as per kidney disease: Improving Global Outcomes Acute
Kidney  Injury  Work  Group,  and  revised  consensus  recommendations  of  the
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International Club of Ascites[24], i.e. increase in serum creatinine ≥ 0.3 mg/dL within 48
h; or a percentage increase serum creatinine ≥ 50% from the baseline which is known,
or presumed, to have occurred within the prior 7 d.
Statistical analysis
The sample size was calculated using Open Epi for proportion, using mortality rate
due  to  infection,  and  AKI  between  36%-38%[16].  Taking  into  account  the  95%
confidence interval (CI), 80% power, and an odds ratio (OR) of 1.5, the final sample
size was approximately 384 CLD patients.
Data were analyzed using Statistical Package for Social Sciences version 20. The
frequency  for  all  variables  was  calculated.  Data  were  expressed  as  a  mean  and
standard deviation for normally distributed continuous variables. The significance of
association  was  calculated  using  the  Student  t-test.  Categorical  variables  were
recorded in their absolute value and analyzed using the chi-squared test. Univariate
analysis was used to identify parameters associated with mortality and morbidity.
Multiple logistic regressions were done in order to identify independent predictors of
poor outcome in these patients. These factors were incorporated in the existing MELD
score. Receiver operating characteristic curves of MELD, MELD-Na, and the new
score were made. Significance tests and CIs were assessed through the nonparametric
bootstrap. The area under the curve was compared between the three scores. Fisher
exact test was used to determine the association of NCDs with predictors of mortality.
All  P  values were two-sided and a P  value of < 0.05 was considered statistically
significant.
RESULTS
Demographics
Records of 399 patients admitted primarily due to decompensation of liver disease
were reviewed. Mean age was 54.3 ± 11.7 years and 64.6% (n = 258) of patients were
male. Hepatitis C was found to be the leading cause of CLD. The length of hospital
stay of more than five days was 18%, while readmission rate within 1 wk was 7%. Six-
week  mortality  was  observed in  13% (n  =  52)  of  patients.  Table  1  describes  the
demographic details of patients.
NCDs  were  present  in  47.4%  (n  =  189)  of  patients.  AKI,  sepsis,  and  non-ST
elevation myocardial infarction (NSTEMI) were present in 41% (n = 165), 17.5% (n =
70), and 1.75% (n = 7) of patients, respectively.
Factors predicting mortality
Upon univariate analysis, hypotension, tachycardia, tachypnea, hypoxia, NSTEMI,
sepsis,  renal  insufficiency,  encephalopathy,  pneumonia,  anemia,  leukocytosis
coagulopathy, high CTP and MELD scores, and frequent admissions in the last 1 to 3
mo were found to be associated with 6 wk mortality.
Upon multivariate analysis, sepsis (OR = 6.50; 95%CI: 3.007-14.06; P < 0.001), AKI
(OR = 2.69; 95%CI: 1.17-6.20; P  = 0.02), and INR (OR = 1.75; 95%CI: 1.14-2.69; P  <
0.001) were significant independent predictors of mortality (Table 2). Figure 1 shows a
flow diagram of 6 wk mortality for patients with advanced cirrhosis and concomitant
sepsis based on the logistic regression model. Sepsis, AKI, and INR were used in a
hierarchical pattern based on the OR.
Factors predicting morbidity
Upon multivariate analysis,  CKD, low albumin, and high MELD-Na scores were
found to be independent factors in predicting morbidity (Table 3).
Factors predicting both mortality and morbidity
Upon multivariate analysis, CKD, high TLC, and high Child class were found to affect
both mortality and morbidity (Table 4).
Addition of sepsis in MELD score
Once the value of sepsis was determined as a significant independent predictor of
mortality based on multivariate analysis, we tried to formulate a new score by adding
a factor of 6.5 into existing MELD scores. This factor was derived from the odds ratio
of sepsis for mortality upon multivariate analysis. The new score labeled as MELD-
sep was found to predict mortality better than MELD and MELD-Na as depicted by
the area under receiver operating characteristic of 0.735 for MELD-sep in contrast
with 0.686 for MELD-Na and 0.671 for MELD score (Figure 2).
Impact of NCDs
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Table 1  Baseline demographic details
Variables
n (%) or
mean ± SD
Age (yr) 54.56 ± 11.74
Gender Male 258 (64.6)
Female 136 (34.4)
Etiology (viral) Hepatitis C 260 (65.1)
Hepatitis B 31 (7.7)
Hepatitis B + Hepatitis D 12 (3)
Hepatitis B + Hepatitis C 6 (1.5)
Non-B, Non-C 61 (15.2)
(Unknown etiology)
Alcohol 20 (5)
Autoimmune hepatitis 8 (2)
Hemochromatosis 1 (0.25)
Duration of chronic liver disease (yr) 4.25 ± 3.71
NCDs Diabetes 148 (37)
Hypertension 96 (24)
Chronic kidney disease 30 (7.5)
Ischemic heart disease 23 (5.7)
Chronic obstructive pulmonary disease 13 (3.2)
Infections on admission Sepsis 70 (17.5)
Lower respiratory tract infection 24 (6)
Urinary tract infection 30 (7.5)
Non-ST Elevation myocardial infarction 7 (1.75)
Stroke 3 (0.75)
Decompensation on admission Ascites 300 (75.1)
Presence of esophageal/gastric varices 235 (58.8)
Portosystemic encephalopathy 170 (42.6)
Acute kidney injury 165 (41.3)
Upper GI bleed 118 (29.5)
Hepatocellular carcinoma 98 (24.5)
Hepatorenal syndrome 86 (21.5)
Spontaneous bacterial peritonitis 76 (19)
Hepato-hydrothorax 12 (3)
Investigations Hemoglobin (g/dL) 9.81 ± 2.17
Total leukocyte count (× 109/L) 9.87 ± 6.17
Platelets (× 109/L) 121.29 ± 108.12
Prothrombin time (s) 17.37 ± 7.87
International normalizing ratio 1.63 ± 0.65
Creatinine (mg/dL) 1.65 ± 1.37
Sodium (mmol/L) 132.3 ± 7.62
Potassium (mmol/L) 4.17 ± 0.88
pH 7.37 ± 0.12
Bicarbonate (mmol/L) 20.13 ± 4.79
Total bilirubin (mg/dL) 5.47 ± 7.57
Alanine transaminase (IU/L) 78.7 ± 128.21
Gama glutamyl transferase (IU/L) 119.26 ± 159.87
Alkaline phosphatase (IU/L) 178.35 ± 133.8
Albumin (g/dL) 2.59 ± 0.58
Child class A 39 (9.8)
B 142 (35.6)
C 218 (54.6)
Prognostic scores MELD score 18.0 ± 8.55
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MELD-Na 21.73 ± 8.31
Charlson index 4.21 ± 1.63
Charlson age adjusted score 5.33 ± 2.20
Outcomes Mortality 52 (13)
Prolong stay 72 (18)
Readmission 28 (7)
NCDs: non-communicable diseases; GI: gastrointestinal; MELD: Model for End-Stage Liver Disease.
NCDs were found to be associated with an increased readmission rate (28.6% without
NCDs vs 71.4% with NCDs; P = 0.03). However, there was no effect on length of stay
(length of stay > 5 d in 51.4% without NCDs vs 48.6% with NCDs; P = 0.45). Upon
multivariate analysis, among all NCDs, only CKD was directly related with increased
morbidity (OR = 3.18; 95%CI: 1.30-7.82; P = 0.01). Moreover, the presence of NCDs
was not found to be an independent predictor of mortality in our series (mortality rate
of 12.4% without NCDs vs  13.9% with NCDs; P  = 0.65). Similarly, the presence of
multiple  comorbid  conditions  did  not  appear  to  impact  the  mortality  directly
(mortality rate of 12.2% without NCDs vs 14.1% with 2 or fewer NCDs vs 15.6% with 3
or more NCDS; P = 0.97). However, the presence of NCDs was directly related with
NSTEMI, which was a major predictor of mortality in our study (Table 5). Similarly,
Charlson  comorbidity  index  was  used  to  calculate  the  burden  of  NCDs  in  our
patients, and this index did not appear to predict the outcome in cirrhotic patients.
DISCUSSION
Decompensated  liver  disease  is  a  state  of  organ  failure  related  to  multi-organ
consequences  such as  encephalopathy,  renal  insufficiency,  volume overload,  GI
bleeding, infections, and frailty[25-28].  In this study of hospitalized decompensated
cirrhotic patients, we evaluated the impact of sepsis and NCDs on patient outcome.
Traditionally, CTP and MELD scores have been used to predict the mortality in
cirrhotic patients. However, the group of patients used to create and validate the
MELD score was devoid of acute reversible complications such as sepsis[29]. Infections
significantly  increase the mortality  in  end-stage liver  disease  with some studies
reporting a 30% death rate in 1 mo[16]. Prevention and treatment of sepsis were shown
to reduce mortality  in  patients  with cirrhosis  and AKI[17].  AKI is  a  common and
overwhelming complication in patients with end-stage liver disease. Belcher et al[15]
also  showed  AKI  to  be  associated  with  high  mortality  and  complications  in
hospitalized patients with cirrhosis. Our study found that AKI, myocardial infarction,
sepsis,  and  coagulopathy  on  admission  were  associated  with  high  mortality  in
cirrhotic patients.
Interestingly,  the  MELD  and  Charlson  comorbidity  index  scores  were  not
associated with high mortality in our analysis. However, high Child class appeared to
affect both mortality and morbidity. Based on our observations, we propose that the
addition of sepsis as a factor in the MELD score gives a better prediction of mortality
as compared to conventional MELD and MELD-Na scores in CLD patients admitted
with acute decompensation. We also found that CKD, low albumin, and high MELD-
Na scores were able to predict morbidity.
Chirapongsathorn et al[30] and Shu et al[31] related longer hospital stays with a high
rate of 30-d readmission while Masadeh et al[32] found the opposite relationship. In our
analysis, prolonged hospital stay was associated with subsequent early readmission
upon  univariate  analysis  but  did  not  stand  out  as  an  independent  factor  upon
multivariate analysis.
The prognostic value of chronic NCDs in cirrhotic patients has not been extensively
studied. Recently,  diabetes has been associated with high mortality[19,33,34],  higher
readmission rate[35],  and a  major  factor  in  determining liver-related outcomes in
cirrhotic  patients[36].  We were unable to  relate  diabetes  directly to  mortality  and
morbidity in our series. However, among NCDs, CKD was found to directly predict
morbidity  in  our  series.  Moreover,  the  presence  of  NCDs  was  associated  with
NSTEMI, which was one of the major predictors of mortality in our cohort.  This
observation indicates NCDs as an important factor that could influence the outcome
of CLD patients independent of well-known prognostic variables incorporated in
Child-Pugh and MELD scores for advanced liver disease patients.
Despite previous studies supporting the use of the Charlson comorbidity index for
prediction of  poor outcome in CLD patients[21,22],  our study did not  find a direct
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Figure 1
Figure 1  Flow diagram of 6 wk mortality for patients with advanced cirrhosis and concomitant sepsis based
on the logistic regression model.  AKI: Acute kidney injury; INR: International normalized ratio.
relationship between Charlson comorbidity index and morbidity upon multivariate
analysis.  This could be due to the difference between patient characteristics.  We
selectively enrolled patients who were admitted due to decompensated liver disease
while  previous  studies  included patients  who were  labeled  as  cirrhotic  in  their
database regardless of compensation status[21,22]. Moreover, the follow-up period was
longer in the Danish cohort[22].
The present study takes into account readmissions at our center. The possibility of
readmissions at other centers was not accounted for. Other limitations include the
cross-sectional design, shorter follow-up, and single center focus. Further large-scale
multicenter studies with a longer follow-up would be helpful in strengthening the
impact of NCDs and sepsis on the determination of outcome in hospitalized cirrhotic
patients.
In conclusion, the addition of sepsis improves the predictability of the MELD score
as a prognostic marker for mortality in patients with decompensated CLD. Presence
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Table 2  Multivariate analysis of factors predicting 6 wk mortality in chronic liver disease
patients
OR (95%CI) P value
NSTEMI No 1
Yes 16.03 (2.01-127.46) 0.009
Sepsis No 1
Yes 6.50 (3.01-14.06) < 0.001
AKI No 1
Yes 2.69 (1.17-6.20) 0.02
INR 1.75 (1.14-2.69) < 0.001
NSTEMI: non-ST-elevation myocardial infarction; AKI: acute kidney injury; INR: international normalized
ratio; OR: odds ratio; CI: confidence interval.
of CKD increases morbidity of patients with CLD.
WJH https://www.wjgnet.com December 27, 2018 Volume 10 Issue 12
Qazi Arisar FA et al. Sepsis and NCDs in cirrhosis
951
Table 3  Multivariate analysis of factors predicting morbidity
OR (95%CI) P value
CKD No 1
Yes 3.18 (1.30-7.82) 0.01
MELD-Na 1.05 (1.01-1.08) 0.005
Albumin 0.55 (0.32-0.92) 0.02
Prolonged hospital stay > 5 d (120 h) or readmission within 7 d of the index admission; CKD: chronic kidney disease; MELD: Model for End-Stage Liver
Disease; OR: odds ratio; CI: confidence interval.
Table 4  Multivariate analysis of factors predicting both mortality and morbidity
OR (95%CI) P value
CKD No 1
Yes 3.12 (1.21-8.06) 0.01
TLC 1.08 (1.03-1.12) < 0.001
Child Class 3.57 (2.20-5.79) < 0.001
CKD: chronic kidney disease; TLC: total leukocyte count; OR: odds ratio; CI: confidence interval.
Table 5  The relationship between predictor of mortality and non-communicable diseases, n (%)
NCDs
P valueYes No
210 (52.6) 189 (47.3)
NSTEMI 7 (3.3) 0 0.01
Sepsis 31 (14.8) 39 (20.6) 0.14
AKI 92 (44.7) 76 (40.2) 0.41
NSTEMI: non-ST-elevation myocardial infarction; INR: international normalized ratio; AKI: acute kidney injury; NCDs: non-communicable diseases.
Figure 2
Figure 2  Receiver operating characteristic curve shows 6 wk mortality prediction of MELD-Sep vs MELD and MELD-Na.  MELD: Model for End-Stage Liver
Disease.
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ARTICLE HIGHLIGHTS
Research background
Patients with decompensated chronic liver disease (CLD) are at high risk of complications.
Various scores have been used to classify the severity of liver disease and to predict mortality.
Recently, diabetes was found to impact mortality in cirrhotic patients. However, the impact of
other comorbidities on mortality and morbidity has not been studied. Moreover, the impact of
sepsis on available predictability scores has not been determined.
Research motivation
Given the  limitations  with  the  use  of  Child-Pugh and Model  for  End-Stage  Liver  Disease
(MELD) scores, we wanted to come up with a new score to predict mortality and morbidity.
Research objective
The objective for  this  study included determination of  sepsis,  non-communicable diseases
(NCDs), and acute kidney injury (AKI) in patients admitted with decompensated liver disease,
along with their impact of NCDs on mortality and morbidity parameters. We also wanted to
evaluate whether the addition of any other variable makes MELD a better tool as a prognostic
marker.
Research methods
We performed a retrospective analysis of medical records of patients with CLD admitted at the
Aga Khan University Hospital. All adult patients with decompensation of CLD (i.e., jaundice,
ascites, encephalopathy, and/or upper gastrointestinal (GI) bleed) as the primary reason for
admission were included. Multivariate analysis was performed to assess predictors of 6 wk
mortality, prolonged hospital stay (> 5 d), and early readmission (within 7 d).
Research results
Six-week mortality rate was 13%. Prolonged hospital stay and readmission rates were 18% and
7%, respectively.  NCDs were present  in 47.4% of  patients.  AKI,  sepsis,  and NSTEMI were
present  in  41%,  17.5%,  and 1.75% patients,  respectively.  Factors  associated with mortality
included AKI, NSTEMI, sepsis, and coagulopathy. The factors found responsible for morbidity
included chronic kidney disease (CKD), low albumin, and high MELD-Na score. By adding
sepsis to the conventional MELD score, the predictability of mortality increased significantly.
CKD was found to impact morbidity independently.
Research conclusion
This  study highlighted multiple  factors  associated with  early  mortality,  readmission,  and
prolonged hospital stay. This study also determined the significance of the addition of sepsis in
the MELD score to improve its predictability as a prognostic marker for mortality in patients
with decompensated CLD. Presence of CKD increased morbidity of patients with CLD.
Research perspective
We need to amend factors linked to mortality, readmission, and prolonged stay not only to
control mortality and morbidity, but also to minimize the cost burden by patients.
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